Noopept
Aliases: GVS-111 · N-fenilacetil-L-prolilglicin etil ester
Last verified: 2026-09-23
The short version
A dipeptide nootropic (prodrug of cycloprolylglycine) — approved in Russia for cognitive disorders. Anxiolytic and neuroprotective, structurally a "peptide piracetam". Key fact: Russian trials for mild cognitive impairment and post-TBI; scarce Western research.
Identity & type
- Molecular type
- peptide
- Origin
- A dipeptide nootropic (prodrug of cycloprolylglycine) — approved in Russia for cognitive disorders.
Mechanism of action
Metabolized to cycloprolylglycine → modulation of glutamatergic (AMPA) and cholinergic systems, increased BDNF/NGF, antioxidant.
not confirmed in humans
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 10–30 mg/day orally (2×10 mg most common).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
10–30 mg/day orally (2×10 mg most common). Mild but consistent effects: clearer focus, verbal fluency, reduced fog; some report headache and irritability at higher doses.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Mild but consistent effects: clearer focus, verbal fluency, reduced fog; some report headache and irritability at higher doses.
Protocol — official vs community
Official / label
Approved in Russia (and some CIS markets) for mild cognitive impairment and post-traumatic brain injury sequelae: 10–30 mg/day orally, given as 10 mg 2–3× daily.
Duration: Russian label practice uses treatment courses of 1.5–3 months; some label schemes run 3 months on, then a month off.
A dipeptide prodrug of cycloprolylglycine. Western regulators have never reviewed it; the supporting trial base is predominantly Russian and low-visibility internationally.
Community (anecdotal)
10–30 mg/day oral, split into 2 doses; sublingual use of the same powder is common for perceived faster onset.
- Cycle:
- Many nootropic users follow the Russian course logic (8–12 weeks on); others take it daily for years.
- Break:
- 1–4 weeks between courses for adherents of the course model.
One of the most-discussed Russian nootropics in Western communities. Reported effects are subtle and subjective; the structured course pattern comes from the Russian label, not from biohacker invention.
Human evidence
Russian trials for mild cognitive impairment and post-TBI; scarce Western research.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Rare: headache, irritability, sleep disturbance if taken late.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics